{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:40Z","timestamp":1787026600877,"version":"build-2736575974"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Molecular therapies, including anti-IgE, biologicals and small molecules are increasingly used for treatment of asthma. The effectiveness of these therapies may be increased with biomarkers. Aim of this study was to assess the value of measuring cumulative IgE levels specific for respiratory allergens to increase the efficacy of anti-IgE therapy for severe bronchial asthma. One hundred and thirty seven patients with severe asthma were recruited from 2016 to 2022. Standard empirical allergy diagnosis (i.e., anamnesis, skin testing, allergen-specific IgE measurement), blood eosinophil counting, measurement of total IgE and of cumulative IgE-specific for respiratory allergens by Phadiatop\u2122 were performed. Thirty four patients with severe allergic asthma, for whom all three diagnostic methods were performed, were then used to analyze the efficacy of anti-IgE treatment in patients stratified in two groups according to cumulative IgE levels specific for respiratory allergens determined by Phadiatop\u2122. Group #1 patients (n = 8) had cumulative specific IgE values \u2265 0.35 and &amp;lt; 1.53 PAU\/l while in group #2 patients (n = 26) they were \u2265 1.53 PAU\/l. Treatment with Omalizumab was performed for at least 12 months. The level of asthma control (ACT questionnaire), the number of asthma exacerbations, the quality of life (AQLQ questionnaire), the need for systemic corticosteroids, and the respiratory function (FEV1) was determined by \u201cbefore-after\u201d analysis for each group, followed by a comparison of the dynamics between groups. In group 2 patients with an initial allergen-specific IgE level \u2265 1.53 kUA\/L, the efficacy of Omalizumab treatment was better regarding asthma control, number of exacerbations, and quality of life than in group 1 patients. Our study provides evidence that measuring cumulative levels of IgE specific for respiratory allergens could be a useful screening method for detecting an allergic phenotype of severe asthma and may serve as biomarker to enhance the success of IgE-targeted therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.941492","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T03:08:10Z","timestamp":1663729690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Cumulative IgE-levels specific for respiratory allergens as biomarker to predict efficacy of anti-IgE-based treatment of severe asthma"],"prefix":"10.3389","volume":"13","author":[{"given":"Veronika","family":"Naumova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Beltyukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Niespodziana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Errhalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Valenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Karaulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darina","family":"Kiseleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"B1","volume-title":"Global initiative for asthma \u2013 GINA 2021","year":"2021"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020","article-title":"Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab","volume":"16","author":"Ridolo","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","article-title":"Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care","volume":"135","author":"Fajt","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08760-x","article-title":"Asthma phenotypes as a guide for current and future biologic therapies","volume":"59","author":"Hamilton","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.10.009","article-title":"Recent advances in severe asthma: From phenotypes to personalized medicine","volume":"157","author":"Schoettler","year":"2020","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/all.13806","article-title":"Toward clinically applicable biomarkers for asthma: An EAACI position paper","volume":"74","author":"Diamant","year":"2019","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.04.011","article-title":"Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine","volume":"65","author":"Agache","year":"2016","journal-title":"Allergol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11080534","article-title":"Metabolic phenotypes in asthmatic adults: Relationship with inflammatory and clinical phenotypes and prognostic implications","volume":"11","author":"Santos","year":"2021","journal-title":"Metabolites"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2015.36.3805","article-title":"FeNO as biomarker for asthma phenotyping and management","volume":"36","author":"Ricciardolo","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.934398","article-title":"Biomarkers of bronchial asthma","volume":"69","author":"Kunc","year":"2020","journal-title":"Physiol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000486856","article-title":"Protein biomarkers in asthma","volume":"175","author":"Karaulov","year":"2018","journal-title":"Int Arch Allergy Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/all.13416","article-title":"EAACI position paper on the standardization of nasal allergen challenges","volume":"73","author":"Aug\u00e9","year":"2018","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/all.13072","article-title":"Allergy in severe asthma","volume":"72","author":"Del Giacco","year":"2017","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594978","article-title":"Microarray-based allergy diagnosis: Quo vadis","volume":"11","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/all.13047","article-title":"Allergy testing in children with persistent asthma: comparison of four diagnostic methods","volume":"72","author":"\u00d6nell","year":"2017","journal-title":"Allergy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1046\/j.1365-2222.1999.00653.x","article-title":"The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT)","volume":"29","author":"Valenta","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12572","article-title":"Microarray-based IgE serology improves management of severe atopic dermatitis in two children","volume":"27","author":"Fedenko","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/v13050915","article-title":"Microarray technology may reveal the contribution of allergen exposure and rhinovirus infections as possible triggers for acute wheezing attacks in preschool children","volume":"13","author":"Niespodziana","year":"2021","journal-title":"Viruses"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1987.tb02034.x","article-title":"Phadiatop\u2013a novel IgE antibody screening test","volume":"17","author":"Merrrett","year":"1987","journal-title":"Clin Allergy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1988.tb00402.x","article-title":"In vitro diagnosis of atopic allergy in children","volume":"43","author":"Gustafsson","year":"1988","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1990.tb00497.x","article-title":"Allergy screening with phadiatop \u00ae and CAP phadiatop \u00ae in combination with a questionnaire in adults with asthma and rhinitis","volume":"45","author":"Eriksson","year":"1990","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1990.tb02660.x","article-title":"The use of phadiatop\u00ae in mass-screening programmes of inhalant allergies: advantages and limitations","volume":"20","author":"Matricardi","year":"1990","journal-title":"Clin Exp Allergy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1990.tb00464.x","article-title":"Evaluation of the phadiatop \u00ae test in an epidemiological study","volume":"45","author":"Wever","year":"1990","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1994.tb00821.x","article-title":"The phadiatop \u00ae test compared with RAST, with the CAP system; proposal for a third phadiatop outcome : \u201cinconclusive\u201d","volume":"49","author":"Crobach","year":"1994","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1998.tb03937.x","article-title":"Current allergic asthma and rhinitis : diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and phadiatop \u00ae) results from 8329 randomized adults from the SAPALDIA study","volume":"53","author":"Tschopp","year":"1998","journal-title":"Allergy"},{"key":"B29","article-title":"Evaluation of the phadiatop\u2122 test in the diagnosis of allergic sensitization in a general adult population","volume":"15","author":"Vidal","year":"2005","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.21037\/atm.2018.04.06","article-title":"The practical benefit of phadiatop test as the first-line in vitro allergen-specific immunoglobulin e (sIgE) screening of aeroallergens among Chinese asthmatics : a validation study","volume":"6","author":"Zeng","year":"2018","journal-title":"Ann Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S292710","article-title":"The role of phadiatop tests and total immunoglobulin e levels in screening aeroallergens: A hospital-based cohort study","volume":"14","author":"Chang","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.1860050313","article-title":"The phadiatop test allows adequate screening for atopy with a marked reduction in cost","volume":"5","author":"Salkie","year":"1991","journal-title":"J Clin Lab Anal"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/7.2.144","article-title":"The phadiatop in vitro test for allergy in general practice: Is it useful","volume":"7","author":"Dekker","year":"1990","journal-title":"Fam Pract"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1988.tb02909.x","article-title":"Diagnosis of allergy in different age groups of children: use of mixed allergen RAST discs, phadiatop and paediatric mix","volume":"18","author":"Zimmerman","year":"1988","journal-title":"Clin Allergy"},{"key":"B35","first-page":"19","article-title":"Determination of the diagnostic efficacy of the multi-RAST test (Phadiotop) in allergic rhinitis","volume":"46","author":"Buj\u00eda","year":"1995","journal-title":"Acta Otor-rinolaringol Esp"},{"key":"B36","article-title":"Evaluation of new test (Phadiatop(\u2122)) for the screening of respiratory allergic disorders in children","volume":"64","author":"Cantani","year":"1990","journal-title":"Ann Allergy"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1991.tb00581.x","article-title":"In vitro screening for inhalant allergy with multi SX 1 RAST\u00ae (Phadiatop\u00ae)","volume":"46","author":"K\u00f6hl","year":"1991","journal-title":"Allergy"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1998.tb03972.x","article-title":"Specific IgE antibodies in the diagnosis of atopic disease. clinical evaluation of a new in vitro test system, UniCAP(\u2122), in six European allergy clinics","volume":"53","author":"Paganelli","year":"1998","journal-title":"Allergy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1081-1206(10)62691-9","article-title":"Efficacy of a single diagnostic test for sensitization to common inhalant allergens","volume":"86","author":"Williams","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.01.004","article-title":"Roles of omalizumab in various allergic diseases","volume":"69","author":"Okayama","year":"2020","journal-title":"Allergol Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5414\/ALX01377E","article-title":"In search of clinically relevant parameters to monitor successful omalizumab therapy in allergic asthma","volume":"2","author":"Probst","year":"2019","journal-title":"Allergol Select"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000260086","article-title":"Xolair is effective in allergics with a low serum IgE level","volume":"152","author":"Ankerst","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13223-020-00479-1","article-title":"Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech anti-IgE registry","volume":"16","author":"Van\u00edk","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02051.x","article-title":"The size of the disease relevant IgE antibody fraction in relation to \u2018total-IgE\u2019 predicts the efficacy of anti-IgE (Xolair) treatment","volume":"64","author":"Johansson","year":"2009","journal-title":"Allergy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02119.x","article-title":"Relationship between pretreatment specific IgE and the response to omalizumab therapy","volume":"64","author":"Wahn","year":"2009","journal-title":"Allergy"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01501-2015","article-title":"Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma","volume":"48","author":"Pillai","year":"2016","journal-title":"Eur Respir J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"B50","volume-title":"Difficult-to-treat asthma in adolescent and adult patients: Diagnosis and management - a GINA pocket guide for health professionals. global strategy for asthma management and prevention","year":"2018"},{"key":"B51","volume-title":"Difficult-to-treat asthma in adolescent and adult patients: Diagnosis and management - a GINA pocket guide for health professionals. global strategy for asthma management and prevention","year":"2019"},{"key":"B52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1398-9995.2011.02728.x","article-title":"Practical guide to skin prick tests in allergy to aeroallergens. global allergy and asthma European network; allergic rhinitis and its impact on asthma","volume":"67","author":"Bousquet","year":"2012","journal-title":"Allergy"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/pai.12563","article-title":"EAACI molecular allergology user\u2019s guide","volume":"23","author":"Matricardi","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. an official American thoracic society and European respiratory society technical statement","volume":"200","author":"Miller","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.001","article-title":"Toward personalization of asthma treatment according to trigger factors","volume":"145","author":"Niespodziana","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-021-00150-z","article-title":"Personalized medicine and allergen immunotherapy: the beginning of a new era","volume":"19","author":"Incorvaia","year":"2021","journal-title":"Clin Mol Allergy"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s41467-018-04591-0","article-title":"PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze","volume":"9","author":"Niespodziana","year":"2018","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201803-0575OC","article-title":"Rhinovirus species-specific antibodies differentially reflect clinical outcomes in health and asthma","volume":"198","author":"Megremis","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.051","article-title":"Maternal allergen-specific IgG might protect the child against allergic sensitization","volume":"144","author":"Lupinek","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21019","article-title":"Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum malassezia-specific IgE: a multicentre, prospective cohort study","volume":"186","author":"Kozera","year":"2022","journal-title":"Br J Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2022.2049588","article-title":"Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease","volume":"31","author":"Ferrucci","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719573","article-title":"The molecular allergen recognition profile in China as basis for allergen-specific immunotherapy","volume":"12","author":"D\u2019souza","year":"2021","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13354","article-title":"IgE-reactivity profiles to allergen molecules in Russian children with and without symptoms of allergy revealed by micro-array analysis","volume":"32","author":"Elisyutina","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15350","article-title":"Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients","volume":"33","author":"Marzano","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13428","article-title":"Co-Occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria","volume":"200","author":"Asero","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.941492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T03:08:25Z","timestamp":1663729705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.941492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2022.941492"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.941492","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"article-number":"941492"}}